Biomedical Patents and the Public's Health
- 25 January 2006
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (4) , 434-437
- https://doi.org/10.1001/jama.295.4.434
Abstract
As a government-sanctioned monopoly, a drug patent allows its owner to prevent others from making, using, or selling a given medication for a set amount of time. Patents can help encourage and reward scientific innovation in the pharmaceutical industry. But some drug companies have been criticized for restricting access to products in the face of actual or potential public health emergencies1 or distorting the patent system in pursuit of higher revenues.2Keywords
This publication has 6 references indexed in Scilit:
- Torcetrapib and Atorvastatin — Should Marketing Drive the Research Agenda?New England Journal of Medicine, 2005
- NIH Declines to March In on Pricing AIDS DrugScience, 2004
- Medication Costs, Adherence, And Health Outcomes Among Medicare BeneficiariesHealth Affairs, 2003
- Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?JAMA, 2001
- Access to Essential Drugs in Poor CountriesA Lost Battle?JAMA, 1999
- Haggling for a Patent: What a Government Would Have to Pay for Prescription Drug PatentsHealth Economics, 1997